CAJ | 학술논문

目的：观察吉西他滨联合替吉奥胶囊治疗晚期食管癌的近期疗效及毒副反应。方法选择29例均经病理证实的晚期食管癌患者，替吉奥80 mg/m2，分2次，餐后口服，d1～d14；吉西他滨1000 mg/m2静脉滴注，d1、d8，21天为1个周期。每2周期后行影像学检查评价疗效、不良反应以及随访情况。结果完全缓解（CR）1例，部分缓解（PR）11例，病情稳定（SD）9例，病情进展（PD）8例，临床总缓解率（CR＋PR）为41．4％，临床获益率（CR＋PR＋SD）为72．4％。毒副反应主要为I-III度骨髓抑制、手足综合征、肝功能损伤、消化道反应等。中位疾病进展时间（mTTP）6．9个月，1年生存率64．3％。结论吉西他滨联合替吉奥胶囊治疗晚期食管癌有一定疗效，患者耐受性好。
목적：관찰길서타빈연합체길오효낭치료만기식관암적근기료효급독부반응。방법선택29례균경병리증실적만기식관암환자，체길오80 mg/m2，분2차，찬후구복，d1～d14；길서타빈1000 mg/m2정맥적주，d1、d8，21천위1개주기。매2주기후행영상학검사평개료효、불량반응이급수방정황。결과완전완해（CR）1례，부분완해（PR）11례，병정은정（SD）9례，병정진전（PD）8례，림상총완해솔（CR＋PR）위41．4％，림상획익솔（CR＋PR＋SD）위72．4％。독부반응주요위I-III도골수억제、수족종합정、간공능손상、소화도반응등。중위질병진전시간（mTTP）6．9개월，1년생존솔64．3％。결론길서타빈연합체길오효낭치료만기식관암유일정료효，환자내수성호。
Objective To evaluate the efficiency and toxicities of Gemcitabine combined with S -1 cap-sule in the treatment of advanced esophageal cancer .Methods Twenty-nine patients with advanced esophageal cancer were treated with S-1 capsule 80 mg/m2 ,twice daily for 14 days and Gemcitabine (1 000 mg/m2 ) was in-travenously administrated on day 1 and 8.The chemotherapy was repeated every 21 days.After two consecutive treatment circles ,the short term efficacy ,adverse effects and follow -up condition were evaluated .Results One case showed complete remission (CR),11cases showed partial remission (PR),9 cases showed stable disease (SD),8 cases showed progressive disease(PD).The responsive rate(CR+PR)was 41.4%;the illness control rate(CR+PR+SD)was 72.4%.The major adverse events were myelosuppression ranging from grade Ⅰto Ⅲ, hand-foot syndrome,disgusting and the damage of liver function .Some patients displayed the damage of liver function.The median time to progress ( mTTP) was 6.9 months.The median 1-year survival rate was 64.3%. Conclusion The combination of Gemcitabine and S -1 capsule is an effective and well -tolerated method for the patients with advanced esophageal cancer .